Activation of the alternative pathway of complement by human serum IgA.

The structure and function of human IgA. Biochem J (1990) 2.65

Defense mechanisms involving Fc-dependent functions of immunoglobulin A and their subversion by bacterial immunoglobulin A proteases. Microbiol Rev (1988) 2.50

Oral microbial ecology and the role of salivary immunoglobulin A. Microbiol Mol Biol Rev (1998) 1.81

The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions. Clin Exp Immunol (1991) 1.68

Killing of Streptococcus pneumoniae by capsular polysaccharide-specific polymeric IgA, complement, and phagocytes. J Clin Invest (1999) 1.32

Decreased circulating C3 levels and mesangial C3 deposition predict renal outcome in patients with IgA nephropathy. PLoS One (2012) 1.08

Pneumococcal polysaccharides complexed with C3d bind to human B lymphocytes via complement receptor type 2. Infect Immun (1991) 1.03

Structural analysis of the N-glycans from human immunoglobulin A1: comparison of normal human serum immunoglobulin A1 with that isolated from patients with rheumatoid arthritis. Biochem J (1994) 1.00

Current Understanding of the Role of Complement in IgA Nephropathy. J Am Soc Nephrol (2015) 0.99

Binding of human IgA1 to rat peritoneal macrophages. Immunology (1988) 0.98

New insights into the pathogenesis of IgA nephropathy. Semin Immunopathol (2014) 0.96

Local release of properdin in the cellular microenvironment: role in pattern recognition and amplification of the alternative pathway of complement. Front Immunol (2013) 0.94

Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglobulin infusion therapy. Clin Exp Immunol (1998) 0.93

Lack of complement activation by human IgA immune complexes. Clin Exp Immunol (1988) 0.90

Enhancement of protective efficacy following intranasal immunization with vaccine plus a nontoxic LTK63 mutant delivered with nanoparticles. Infect Immun (2002) 0.90

An acute model for IgA-mediated glomerular inflammation in rats induced by monoclonal polymeric rat IgA antibodies. Clin Exp Immunol (1993) 0.89

In vivo activation of complement by IgA in a rat model. Clin Exp Immunol (1992) 0.88

The role of the carbohydrate chains in complement (C3) fixation by solid-phase-bound human IgA. Immunology (1994) 0.86

Prolonged and preferential production of polymeric immunoglobulin A in response to Streptococcus pneumoniae capsular polysaccharides. Infect Immun (1996) 0.85

Monoclonal Antibodies of a Diverse Isotype Induced by an O-Antigen Glycoconjugate Vaccine Mediate In Vitro and In Vivo Killing of African Invasive Nontyphoidal Salmonella. Infect Immun (2015) 0.83

The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy. Front Immunol (2016) 0.83

Induction of IgM, IgA and IgE antibodies in colorectal cancer patients vaccinated with a recombinant CEA protein. J Clin Immunol (2012) 0.82

Clearance kinetics and tissue distribution of aggregated human serum IgA in rats. Immunology (1989) 0.81

Complement-coated antibody-transfer (CCAT); serum IgA1 antibodies intercept and transport C4 and C3 fragments and preserve IgG1 deployment (PGD). Mol Immunol (2005) 0.81

Binding, internalization and degradation of soluble aggregates of human secretory IgA by resident rat peritoneal macrophages. Immunology (1988) 0.81

Relationship between serum IgA/C3 ratio and severity of histological lesions using the Oxford classification in children with IgA nephropathy. Pediatr Nephrol (2014) 0.79

Fine Mapping Implicates a Deletion of CFHR1 and CFHR3 in Protection from IgA Nephropathy in Han Chinese. J Am Soc Nephrol (2016) 0.79

Fc receptor function and circulating immune complexes in gluten sensitive enteropathy--possible significance of serum IgA. Gut (1991) 0.79

C4d deposits in IgA nephropathy: where does complement activation come from? Pediatr Nephrol (2017) 0.78

Anti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells. Haematologica (2012) 0.78

Complement-mediated enhancement of IgA-induced H2O2 release by human polymorphonuclear leucocytes. Immunology (1989) 0.77

IgA nephropathy associated with a novel N-terminal mutation in factor H. Eur J Pediatr (2010) 0.77

C3, C4, factor B and HLA-DR alpha mRNA expression in renal biopsy specimens from patients with IgA nephropathy. Immunology (1995) 0.76

The solution structures of native and patient monomeric human IgA1 reveal asymmetric extended structures: implications for function and IgAN disease. Biochem J (2015) 0.75

Implication of urinary complement factor H in the progression of immunoglobulin A nephropathy. PLoS One (2015) 0.75

The interaction between circulating complement proteins and cutaneous microvascular endothelial cells in the development of childhood Henoch-Schönlein Purpura. PLoS One (2015) 0.75

Glomerular abundance of complement proteins characterized by proteomic analysis of laser-captured microdissected glomeruli associates with progressive disease in IgA nephropathy. Clin Proteomics (2017) 0.75

Circulating complement factor H-related proteins 1 and 5 correlate with disease activity in IgA nephropathy. Kidney Int (2017) 0.75

Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci U S A (1976) 6.65

Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int (1998) 4.31

Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum (1997) 3.80

Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood (2001) 3.49

Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum (1996) 2.96

IFN-gamma-induced L-arginine-dependent toxoplasmastatic activity in murine peritoneal macrophages is mediated by endogenous tumor necrosis factor-alpha. J Immunol (1992) 2.73

Innate immunity in the lung: how epithelial cells fight against respiratory pathogens. Eur Respir J (2004) 2.70

C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol (1976) 2.64

Requirement of extracellular complement and immunoglobulin for intracellular killing of micro-organisms by human monocytes. J Clin Invest (1979) 2.42

Complement in organ transplantation. Contributions to inflammation, injury, and rejection. Transplantation (1995) 2.36

Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum (1995) 2.25

Repeatability of cellular and soluble markers of inflammation in induced sputum from patients with asthma. Eur Respir J (1996) 2.05

Acquired antithrombin III deficiency and thrombosis in the nephrotic syndrome. Am J Med (1978) 1.94

Resistance to both complement activation and phagocytosis in type 3 pneumococci is mediated by the binding of complement regulatory protein factor H. Infect Immun (1999) 1.87

The value of indirect immunofluorescence and solid phase techniques for ANCA detection. A report on the first phase of an international cooperative study on the standardization of ANCA assays. EEC/BCR Group for ANCA Assay Standardization. J Immunol Methods (1993) 1.86

The current status of neutrophil cytoplasmic antibodies. Clin Exp Immunol (1989) 1.78

Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Methods (2004) 1.78

Effect of experimental rhinovirus 16 colds on airway hyperresponsiveness to histamine and interleukin-8 in nasal lavage in asthmatic subjects in vivo. Clin Exp Allergy (1997) 1.76

Participation of immunoglobulins and complement components in the intracellular killing of Staphylococcus aureus and Escherichia coli by human granulocytes. Infect Immun (1981) 1.74

Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation. Lung Cancer (2006) 1.61

Association and dissociation of aggregated IgG from rat peritoneal macrophages. J Exp Med (1977) 1.61

Overexpression of the alpha v beta 6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival. J Pathol (2007) 1.60

Relation between duration of smoking cessation and bronchial inflammation in COPD. Thorax (2005) 1.60

Aggregated human immunoglobulin G stabilized by albumin: a standard for immune complex detection. J Immunol Methods (1979) 1.60

Genetic variants of microsomal epoxide hydrolase and glutamate-cysteine ligase in COPD. Eur Respir J (2008) 1.59

Transforming growth factor beta1 and recruitment of macrophages and mast cells in airways in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1998) 1.59

T cells cloned from human rheumatoid synovial membrane functionally represent the Th1 subset. Scand J Immunol (1992) 1.58

A pathogenic role for secretory IgA in IgA nephropathy. Kidney Int (2006) 1.58

Imaging of bacterial infections with 99mTc-labeled human neutrophil peptide-1. J Nucl Med (1999) 1.57

CD24(hi)CD27(+) B cells from patients with allergic asthma have impaired regulatory activity in response to lipopolysaccharide. Clin Exp Allergy (2014) 1.56

Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci U S A (2001) 1.55

Experimental rhinovirus 16 infection. Effects on cell differentials and soluble markers in sputum in asthmatic subjects. Am J Respir Crit Care Med (1997) 1.55

Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD. J Pathol (2000) 1.54

Interaction between human neutrophils and zymosan particles: the role of opsonins and divalent cations. J Immunol (1981) 1.51

C3 requirements for formation of alternative pathway C5 convertase. J Immunol (1976) 1.50

The glomerular deposition of PAS positive material correlates with renal function in human kidney diseases. Clin Nephrol (1997) 1.48

Interleukin-17 activates human renal epithelial cells in vitro and is expressed during renal allograft rejection. J Am Soc Nephrol (1998) 1.47

Bone marrow IgA and IgA subclass synthesis in ankylosing spondylitis. J Rheumatol (1992) 1.47

Antineutrophil cytoplasmic autoantibodies: a review of the antigens involved, the assays, and the clinical and possible pathogenetic consequences. Blood (1993) 1.46

Variation in the tumour necrosis factor gene is not associated with susceptibility to COPD. Eur Respir J (2007) 1.45

Why do child mortality rates fall? An analysis of the Nicaraguan experience. Am J Public Health (1991) 1.45

The effect of calcineurin inhibitors and corticosteroids on the differentiation of human dendritic cells. Eur J Immunol (2000) 1.45

Circulating IgA-immune complexes in Henoch-Schönlein purpura. A longitudinal study of their relationship to disease activity and vascular deposition of IgA. Am J Med (1980) 1.44

Antilactoferrin antibodies in patients with rheumatoid arthritis are associated with vasculitis. Arthritis Rheum (1992) 1.44

Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol (2001) 1.41

Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways. Arthritis Rheum (2009) 1.40

Antileukoprotease: an endogenous protein in the innate mucosal defense against fungi. J Infect Dis (1997) 1.39

Isolation of alternative pathway C3 convertase containing uncleaved B and formed in the presence of C3 nephritic factor (C3neF). J Immunol (1976) 1.38

The role of complement in the binding and degradation of immunoglobulin aggregates by macrophages. J Immunol (1979) 1.36

Enhanced degradation of soluble immunoglobulin aggregates by macrophages in the presence of complement. Immunology (1979) 1.35

Effect of defensins on interleukin-8 synthesis in airway epithelial cells. Am J Physiol (1997) 1.34

The value of complement and immune complex determinations in monitoring disease activity in patients with systemic lupus erythematosus. Arthritis Rheum (1985) 1.34

Interleukin-17 and CD40-ligand synergistically enhance cytokine and chemokine production by renal epithelial cells. J Am Soc Nephrol (2000) 1.32

Circulating and mesangial secretory component-binding IgA-1 in primary IgA nephropathy. Kidney Int (1984) 1.32

Assessment of complement deficiency in patients with meningococcal disease in The Netherlands. Clin Infect Dis (1999) 1.30

IgA- and secretory IgA-opsonized S. aureus induce a respiratory burst and phagocytosis by polymorphonuclear leucocytes. Immunology (1987) 1.30

Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus. Am J Kidney Dis (1995) 1.29

Production and cytokine-mediated regulation of monocyte chemoattractant protein-1 by human proximal tubular epithelial cells. Kidney Int (1995) 1.29

The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis. J Thromb Haemost (2006) 1.28

Expression of adhesion molecules in early rheumatoid synovial tissue. Clin Immunol Immunopathol (1995) 1.27

Immunoglobulin production by human peripheral lymphocytes induced by anti-C3 receptor antibodies. J Immunol (1984) 1.26

Regulation of secretory leukocyte proteinase inhibitor (SLPI) production by human bronchial epithelial cells: increase of cell-associated SLPI by neutrophil elastase. J Investig Med (2000) 1.26

Interleukin 2 mediates stimulation of complement C3 biosynthesis in human proximal tubular epithelial cells. J Clin Invest (1991) 1.25

Antibacterial activity of human neutrophil defensins in experimental infections in mice is accompanied by increased leukocyte accumulation. J Clin Invest (1998) 1.25

Chronic obstructive pulmonary disease: role of bronchiolar mast cells and macrophages. Am J Pathol (1997) 1.25

Complement deficiency predisposes for meningitis due to nongroupable meningococci and Neisseria-related bacteria. Clin Infect Dis (1994) 1.24

Induction of SLPI (ALP/HUSI-I) in epidermal keratinocytes. J Invest Dermatol (1998) 1.24

Opsonic recognition of staphylococci mediated by cell wall peptidoglycan: antibody-independent activation of human complement and opsonic activity of peptidoglycan antibodies. J Immunol (1980) 1.21

Defensins: key players or bystanders in infection, injury, and repair in the lung? J Allergy Clin Immunol (1999) 1.21

Proteases from Aspergillus fumigatus induce release of proinflammatory cytokines and cell detachment in airway epithelial cell lines. J Infect Dis (1997) 1.21

Heterogeneity, polypeptide chain composition and antigenic reactivity of C3 nephritic factor. J Immunol (1978) 1.21

Human neutrophil defensin and serpins form complexes and inactivate each other. Am J Respir Cell Mol Biol (1995) 1.20

Presence of circulating macromolecular IgA in patients with hematuria due to primary IgA nephropathy. Am J Med (1983) 1.19

The tetracycline derivative minocycline differentially affects cytokine production by monocytes and T lymphocytes. Antimicrob Agents Chemother (1996) 1.18

Granzyme-positive cytotoxic cells are specifically increased in early rheumatoid synovial tissue. Arthritis Rheum (1994) 1.17

Analysis of neutrophil-derived antimicrobial peptides in gingival crevicular fluid suggests importance of cathelicidin LL-37 in the innate immune response against periodontogenic bacteria. Oral Microbiol Immunol (2008) 1.17

Analysis of lymphoid and dendritic cells in human lymph node, tonsil and spleen. A study using monoclonal and heterologous antibodies. Virchows Arch B Cell Pathol Incl Mol Pathol (1984) 1.17

Anti-endothelial cell antibodies in patients with rheumatoid arthritis complicated by vasculitis. Clin Exp Immunol (1989) 1.17

Rapamycin induces apoptosis in monocyte- and CD34-derived dendritic cells but not in monocytes and macrophages. Blood (2001) 1.16

Increased expression of IL-15 in the synovium of patients with rheumatoid arthritis compared with patients with Yersinia-induced arthritis and osteoarthritis. J Pathol (1997) 1.16

Activation of complement by human serum IgA, secretory IgA and IgA1 fragments. Mol Immunol (1988) 1.15

Effects of C-1 on the size of soluble immune aggregates and on their processing by macrophages. J Immunol (1979) 1.15

Effect of neutrophil serine proteinases and defensins on lung epithelial cells: modulation of cytotoxicity and IL-8 production. J Leukoc Biol (1997) 1.14

Proteinase 3, the major autoantigen of Wegener's granulomatosis, enhances IL-8 production by endothelial cells in vitro. J Am Soc Nephrol (1996) 1.14

Stabilization of the classical pathway C3 convertase C42, by a factor F-42, isolated from serum of patients with systemic lupus erythematosus. Immunology (1980) 1.14

Relative resistance of the F-42-stabilized classical pathway C3 convertase to inactivation by C4-binding protein. J Immunol (1980) 1.13

Initiation of apoptosis by actin cytoskeletal derangement in human airway epithelial cells. Am J Respir Cell Mol Biol (2001) 1.13

Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation. Blood (1999) 1.13

Diagnostic efficacy and prognostic value of serum procalcitonin concentration in patients with suspected sepsis. J Intensive Care Med (2008) 1.12